Regeneron Pharmaceuticals (REGN, Financial) witnessed a notable stock price increase of approximately 4.53% after it released its impressive fourth-quarter and full-year 2024 earnings report. This performance significantly outpaced market expectations, as reflected by the company's stock movement.
In its recent earnings release, Regeneron (REGN, Financial) reported a 10% year-over-year revenue growth, reaching close to $3.79 billion. The non-GAAP net income also saw a modest rise of 2%, totaling $1.39 billion or $12.07 per share. These results not only exceeded the analyst forecasts of $3.76 billion in revenue and $11.27 per share in adjusted net income but also fueled the stock's upward momentum.
A significant contributor to these results was a 2% increase in sales of Eylea, a treatment for retina disorders, which generated just under $1.5 billion. Additionally, Regeneron's cancer drug Libtayo saw sales jump by an impressive 50%, amounting to $367 million. The company's revenue from collaborations with Sanofi and Bayer also rose by 17%, reaching nearly $1.61 billion, further strengthening its financial position.
Looking ahead to 2025, Regeneron (REGN, Financial) has projected its expenses, with expectations of non-GAAP research and development costs ranging between $5 billion and $5.2 billion, and capital expenditures projected between $850 million to $975 million. However, the company has not provided specific revenue or profit forecasts for the upcoming year.
On the stock analysis front, Regeneron (REGN, Financial) displayed strong financial metrics. The company's current market capitalization stands at $76.60 billion, with a PE ratio of 17.25 and a PB ratio of 2.62, indicating solid valuation metrics given the current stock price of $697.05. Notably, Regeneron's stock is considered "Modestly Undervalued" according to its GF Value of $852.32, suggesting potential for future growth.
With strong financial health, Regeneron (REGN, Financial) exemplifies robust financial strength, as evidenced by its high Altman Z-score of 7.88 and a comfortable interest coverage ratio of 64.93. These indicators suggest that the company is well-positioned to manage its financial obligations and continue its growth trajectory.
Investors should note that despite significant insider selling over the past 12 months, the company's substantial institutional ownership of 83.43% reflects confidence from major investors. Regeneron (REGN, Financial) continues to deliver strong operational performance while maintaining a solid balance sheet, positioning it favorably for future opportunities in the biotechnology sector.
